Lonza Group AG
SIX:LONN

Watchlist Manager
Lonza Group AG Logo
Lonza Group AG
SIX:LONN
Watchlist
Price: 532.4 CHF 0.26% Market Closed
Market Cap: 38.5B CHF
Have any thoughts about
Lonza Group AG?
Write Note

Gross Margin
Lonza Group AG

29.2%
Current
37%
Average
44%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
29.2%
=
Gross Profit
2B
/
Revenue
6.7B

Gross Margin Across Competitors

Country CH
Market Cap 38.4B CHF
Gross Margin
29%
Country US
Market Cap 1.2T USD
Gross Margin
55%
Country US
Market Cap 202.3B USD
Gross Margin
41%
Country US
Market Cap 166.6B USD
Gross Margin
60%
Country KR
Market Cap 66.8T KRW
Gross Margin
49%
Country US
Market Cap 38.8B USD
Gross Margin
55%
Country US
Market Cap 36.2B USD
Gross Margin
35%
Country US
Market Cap 27B USD
Gross Margin
59%
Country US
Market Cap 24B USD
Gross Margin
35%
Country CN
Market Cap 164.4B CNY
Gross Margin
40%
Country US
Market Cap 22.2B USD
Gross Margin
60%
No Stocks Found

Lonza Group AG
Glance View

Market Cap
38.4B CHF
Industry
Life Sciences Tools & Services

Amidst the serene valleys and bustling innovation hubs of Switzerland, Lonza Group AG has carved an indelible niche in the dynamic world of life sciences. Established in 1897, this stalwart of the biotech and pharmaceutical industry seamlessly blends traditional Swiss precision with cutting-edge scientific inquiry. Originally a chemical company, Lonza has reinvented itself over the years, today standing as a leading global provider of integrated solutions for the pharmaceutical, biotechnology, and nutrition sectors. From delivering small molecules and complex biologics to pioneering innovations in cell and gene therapy, Lonza's versatile and expansive portfolio underscores its core strength: fostering the seamless transition from early-stage research to full-scale manufacturing. This unique capability leverages a vast network of state-of-the-art facilities and expert talent, enabling Lonza to nurture groundbreaking therapies from concept through to market readiness. The secret to Lonza's business model lies in its adept mix of contract development and manufacturing (CDMO) services, enabling it to partner with a diverse clientele ranging from nimble biotechs to giant pharmaceutical firms. This breadth of collaboration adds a layer of stability and scale to its operations, generating revenue through long-term manufacturing agreements and comprehensive development programs. Lonza thrives on its ability to tailor its offerings, providing customized support at various stages of a drug’s lifecycle — from early discovery to commercial supply. Furthermore, their expansion into high-growth areas such as personalized medicine and biotechnology bolsters their competitive edge while aligning with market demand trends. This strategic alignment, coupled with a relentless pursuit of operational excellence and innovation, propels Lonza's enduring legacy as both a powerhouse and a partner in forging the future of medicine.

LONN Intrinsic Value
667.83 CHF
Undervaluation 20%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
29.2%
=
Gross Profit
2B
/
Revenue
6.7B
What is the Gross Margin of Lonza Group AG?

Based on Lonza Group AG's most recent financial statements, the company has Gross Margin of 29.2%.